Prestige Bio Pharma Group Participates in BIO USA... "Strengthening the Status of K-Bio Innovation"

Prestige BioPharma Group, a company specializing in antibody pharmaceuticals, announced on the 25th that it will participate in the world's largest pharmaceutical and biotechnology exhibition, the '2023 BIO International Convention (BIO USA),' held in Boston, USA, from June 5 to 8. Prestige BioPharma (CEO Park So-yeon) and Prestige BioLogics (CEO Hyun Deok-hoon) will set up exhibition booths and both participate in the event. This will serve as a stepping stone to strengthen full value chain partnerships and prepare partnering activities with various global big pharma companies, aiming to become a leading company in the global market.

This is the first official simultaneous participation of the two representative companies of the Prestige BioPharma Group at BIO USA. The group will showcase its core competencies in various ways at an independent booth, not within the K-Bio joint pavilion, and invite GMP contract manufacturing interested customers to its manufacturing facility in Osong, Chungbuk, South Korea, via an OLED touchscreen installed in the booth. Additionally, a separate space will be arranged for multiple meetings with global pharmaceutical companies to conduct numerous contract-related business networking activities.

In particular, at KBTP (Korea Bio-tech Partnership), hosted by the Korea Bio Association, where global VCs and VIPs from around the world will be present, Chairperson Park So-yeon will personally conduct IR pitching to promote the status of K-Bio. Since this event is an exhibition with participation from over 8,000 pharmaceutical and biotech companies from 65 countries worldwide, key executives including Prestige BioPharma Chairperson Park So-yeon, Vice Chairman Kim Jin-woo, and Michael Rupert, Head of Business Development, will participate. Prestige BioLogics will also maximize promotional activities through company introduction presentations at the K-Start up event hosted by the Korea Bio Pharmaceutical Association.

Prestige BioPharma Group will focus on promoting to major global customers that it is a company with a full value chain integrating the entire lifecycle of pharmaceuticals from research and development to production. Prestige BioPharma, as an antibody drug developer, will introduce various R&D achievements including the Herceptin biosimilar ‘HD201 (Tuznue),’ which is about to apply for marketing authorization with the European Medicines Agency, while Prestige BioLogics will seek new customers by showcasing its contract development and manufacturing organization (CDMO) production capacity of 154,000 liters.

Prestige BioLogics, which will be intensively introduced at this event, plans to actively promote its services to global companies and potential customers focusing on expertise and cases related to biotechnological innovation, thereby establishing its position as an innovative CDMO. Based on experience in biosimilar and antibody new drug development and manufacturing, the company will introduce proprietary technologies for process innovation and biopharmaceutical productivity improvement, and share cases of process efficiency improvement using scale-out to actively pursue sales activities that can lead to actual contract results.

A representative of Prestige BioPharma Group stated, “The primary goal of this event is to firmly establish the presence of the two K-Bio companies by actively participating in the IR event hosted by the Korea Bio Association,” adding, “Introducing the company to more enterprises, demonstrating stable manufacturing capabilities that meet customer requirements, and achieving actual contract manufacturing results are key objectives.” He continued, “With the long-awaited first marketing authorization application of Prestige BioPharma imminent, we will confidently do our best to ensure that large-scale orders for Prestige BioLogics are realized.”